Physician profile
Macey M C Luo-Souza
NPI 1891947669
$11,492.25
in general payments reported to CMS, 2019-2025
18 companies · $3,970 in 2025
The $3,970 reported for 2025 was more than what 99% of Psychiatric/Mental Health, Child & Adolescent (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $315).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $929 · 2022: $2,873 · 2023: $2,020 · 2024: $1,700 · 2025: $3,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,683 · Education: $7.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,683.47 |
| Education | $7.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,556.42 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,773.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,296.63 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,211.68 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $1,140.94 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $618.36 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $592.14 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $466.40 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $345.20 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $284.06 | 2025 | Cobenfy |
| Indivior INC. | $276.35 | 2023-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $275.50 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $232.32 | 2022-2023 | Trintellix |
| Axsome Therapeutics, INC. | $204.32 | 2024-2025 | Auvelity |
| Sage Therapeutics, LLC | $109.89 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $69.93 | 2023 | Quviviq |
| Luye Pharma (USA) Ltd. | $22.83 | 2025 | Erzofri Extended-Release |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.03 | 2025 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macey Luo-Souza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.